Human FARS2 activation kit by CRISPRa

CAT#: GA107314

FARS2 CRISPRa kit - CRISPR gene activation of human phenylalanyl-tRNA synthetase 2, mitochondrial



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
FARS2 rabbit polyclonal antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00


FARS2 (Myc-DDK-tagged)-Human phenylalanyl-tRNA synthetase 2, mitochondrial (FARS2), nuclear gene encoding mitochondrial protein
    • 10 ug

CNY 3,656.00
CNY 3,990.00


FARS2 Rabbit polyclonal Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol FARS2
Locus ID 10667
Kit Components

GA107314G1, FARS2 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA107314G2, FARS2 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA107314G3, FARS2 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001318872, NM_006567
Synonyms COXPD14; FARS1; HSPC320; PheRS; SPG77
Summary This gene encodes a protein that transfers phenylalanine to its cognate tRNA. This protein localizes to the mitochondrion and plays a role in mitochondrial protein translation. Mutations in this gene can cause combined oxidative phosphorylation deficiency 14 (Alpers encephalopathy). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...